Published in final edited form as:

Curr Bladder Dysfunct Rep. 2019 ; 14(4): 331–341. doi:10.1007/s11884-019-00543-6.

The Bladder is Not Sterile: an Update on the Urinary Microbiome

A. Lenore Ackerman¹, Toby C. Chai²

¹Cedars-Sinai Medical Center, 99 N. La Cienega Blvd. Suite M102, Beverly Hills, CA 90211, USA

²Boston Medical Center, Boston University School of Medicine, 725 Albany St., Suite 3B, Shapiro Building, Boston, MA 02118, USA

Abstract

Purpose of Review—The article discusses (1) techniques used to study bacterial urinary microbiota; (2) existence of non-bacterial urinary microbiota; (3) associations between changes in urinary microbiota and various benign lower urinary tract disorders.

Recent Findings—Urine harbors a diverse microbial community that resides within it. A multitude of studies have identified differences in these communities associated with urologic conditions, suggesting that microbial communities may maintain normal bladder homeostasis. Technological advances in analytic approaches have improved our understanding of the urinary microbiome. The choice of urine sampling method (voided, catheterized, or aspirated) will significantly influence microbiome findings. Sex and age highly influence urinary microbiota; in addition to rigorous inclusion criteria, microbial studies must be sufficiently powered to overcome the substantial interindividual variability of urinary microbiota. Regardless of these complicating factors, studies have identified microbial patterns correlating with both urologic diagnoses and treatment responses.

Summary—Without a clear understanding of the variability of and exogenous influences on the urinary microbiota in the absence of disease, it has been challenging to reveal the microbial patterns responsible for disease pathophysiology. Host mechanisms in response to the urinary microbiome are also poorly understood. Additional research can address whether the manipulation of urinary microbiota will benefit lower urinary tract health.

Keywords

Urinary microbiome; Benign lower urinary tract disorders

Introduction

The healthy bladder is not sterile. Urine harbors a complex microbial community even in healthy, asymptomatic individuals. This microbial community is thought to perform critical

Toby C. Chai, toby.chai@bmc.org.

Conflict of Interest A. Lenore Ackerman has no conflict of interest. Toby C. Chai has no conflict of interest.

Human and Animal Rights and Informed Consent The authors did not perform any studies with human or animal subjects in this review article.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

functions in bladder homeostasis, with potential roles in the maintenance of urothelial integrity, protection against infection, regulation of neurotransmission, and promotion of normal immune function [1]. Shifts in resident urinary microbiota towards different communities that do not perform these beneficial functions are termed dysbiosis, such imbalances have been implicated in dysfunction of nearly every organ system, from the central nervous system to the genitourinary tract (Fig. 1). Highly sensitive, culture-based, and state-of-the-art culture-independent techniques have opened a window into understanding these communities (reviewed in [2]). Detection of a microbial community in urine specimens, however, cannot presume an identical microbial community within or on tissue of either the lower (bladder, prostate, urethra) or upper (ureter, renal pelvis) urinary tract. In comparison with other body sites, there remains a substantial gap between curiosity about urinary microbes and our understanding of their role in urologic symptomatology. Of the literature identified preparing this review, approximately half of PubMed-indexed articles concerning the urinary microbiota were reviews lacking primary data. While a decade of study has revealed fundamental roles for the microbiota in health and disease in other systems, multiple technical and operational challenges specific to the urinary tract have challenged progress to understanding the urinary microbiome's specific functions.

Technical Challenges

Deep sequencing of variable regions within the 16S rRNA locus (commonly referred to as next-generation sequencing (NGS)) remains the most common methodology to examine bacterial populations. Several important limitations to this technology are particularly relevant to the analysis of urinary populations, and urine presents unique technical challenges requiring special consideration before applying standard techniques and pipelines used for other biological samples. In contrast to stool, which contains ample bacteria, urine contains low numbers of microbes and significant host material in shed urothelial cells. To date, numerous studies have demonstrated a significant influence on the results of population analyses of collection technique, sample volume, DNA extraction methodologies, choice of consensus sequencing region and database for taxonomic assignment, and computational analysis for data interpretation [3•, 4•, 5, 6]. Even in higher biomass samples, such as stool, such choices influence results, producing disparate findings for similar studies with small variations in analytic approaches [7-10].

Standardized collection methods and analytic approaches may improve the reliability and scalability of independent studies, but as technology develops, continual refinement will be needed to address the limitations of culture-independent microbial profiling. Given the low biomass of urine samples, the intrinsic error rates of standard NGS can produce significant inaccuracy. In addition, contaminants, such as environmental, skin or vaginal microbes, and urothelial cells, can be amplified to levels similar to those of the community under analysis, creating considerable confounders [6]. The use of larger volume samples and more stringent lysis conditions improves microbial community representation [5, 11]. There have also been intriguing advances, such as PacBio circular consensus sequencing (CCS); sequencing and error-correcting of full-length bacterial 16S rRNA genes provides high-fidelity species-level microbiome data unobtainable with standard NGS [12]. Regardless of method, recognition of the biases in multiple decisions inherent for any individual study prompts caution in

relying on any single study as conclusive in our exploration of the urinary microbiome and reinforces the need for confirmatory analyses using alternative approaches.

Defining Pathologic Changes in the Urinary Microbiota

To an extent, early studies of urinary microbes bypassed the iterative nature of scientific exploration, attempting to identify pathognomonic bacteria for urologic diseases without first establishing the techniques needed for the study of urinary populations, reaching consensus on what defines normal or even that urinary microbiota represent the bladder environment.

Problematic is the proximity of the lower urinary tract (LUT) to higher biomass sites, such as the vagina, through which urine is typically sampled. Only one study looked at the microbiome of urinary samples collected by suprapubic aspirates [4•]. Large differences were found between urinary microbial communities collected by suprapubic aspiration from those seen in voided samples from matched patients, with voided samples exhibiting more similarity to matched vaginal samples. Catheterized samples were far more similar to aspirates, but these catheterizations were performed after sterile, surgical preparation of the urethra. Even under these conditions, catheterized samples contained more vaginal commensals (e.g., *Lactobacillus*, *Prevotella*, *Atopobium*) than aspirated samples. Operating room-based catheterization represents a different scenario than clinic-based catheterization, which will likely contain more genital flora. Suprapubic aspiration is impractical for routine studies, voided samples contain substantial contaminant microorganisms from neighboring urogenital sites, and catheterization reduces but does not eliminate that sampling contamination [13].

Also, there is no guarantee that the urinary microbiome, even when sampled by aspiration, reflects the bladder microbiome. In the gut, the microbial content of stool does not mirror that of the colonic mucosa [14, 15]. Microbes present within bladder tissue or at the bladder-urine interface are presumably selected for different environmental pressures than those in urine; the bladder-associated microbiome likely differs from urinary microbiota. This debate returns us to the question of why we study the urinary microbiome. Most studies seek biomarkers of disease in the hopes that recognizable alterations in urinary flora can provide clinically useful information about diagnosis, prognosis, or causative pathology. The appropriate urine specimen to study may therefore differ for the question being asked; for this reason, the study of voided urine, while generally less specific for the LUT, may serve a more valuable purpose if the goal is identifying diagnostic or prognostic, non-invasive biomarkers. Suprapubic aspirates, while likely to be most representative of the true LUT urinary microbiome, may still be insufficient to understand bladder pathophysiology if the disease is mediated at the microbe-urothelial interface.

A recent comparison of bacteria isolated from gastrointestinal, vaginal, and urinary samples revealed strong similarities between the vaginal and urinary microbiota, which were distinct from the gastrointestinal microbiota. Whole-genome phylogenetic analyses of bacterial strains isolated from the vagina and bladder within single subjects were similar and differed from isolates catalogued from stool. The authors suggested the possibility of interlinked

urogenital microbiota, at least in women, which may reframe how we understand microbiota-related pathologies and potential interventions [16••].

Defining urotypes

In addition to technical challenges, difficulties defining experimental and control populations confound many current studies. Some of the best evidence linking the urinary microbiome exist for urgency incontinence, a condition that is more objectively defined than a subjectively defined symptom cluster lacking objective diagnostic criteria, such as interstitial cystitis/bladder pain syndrome (IC/BPS) or chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Given substantial interindividual variability and intraindividual variation over time, large sample groups and longitudinal samples, particularly with monitoring of symptom fluctuations, may be necessary to overcome these limitations.

Instead of attempting to examine hundreds of taxa independently, several research groups have separated patients into low and high diversity groups, observing associations of these categories with urologic conditions from bladder cancer to IC/BPS [2, 17-19, 20•, 21, 22•, 23, 24]. Most studies, however, did not utilize an age-matched control cohort; the higher diversity group tended to reflect an older patient population for which age and menopausal status, not disease, may be the dominant influence. At least in women, age and menopausal status are associated with urinary microbial differences [17, 25-28], the magnitudes of which can exceed those associated with disease states. Rigorous matching is needed to avoid artifactual findings, particularly in age-associated conditions such as overactive bladder (OAB). Consensus on appropriate ways to structure both subject and control populations will allow faster progress in understanding types of dysbiosis.

The role of microbial diversity as a measure of disease must take these baseline differences into account. For younger women, in whom the microbiome is less diverse, increasing diversity may be the pathologic state; for older women, who are more diverse at baseline, decreased diversity may represent dysbiosis. Thus, while diversity measures can be helpful descriptors, their meaning is often confused or overstated. Many indices factor in both evenness and richness, which can lead to false equivalency between bacterial communities. The need for diversity measures to describe differences in urinary communities reflects a lack of simple associations of diseases with single organisms and emphasizes the complex interdependency between disease, host health and immune status, and the complex resident microbial community (including bacteria and the frequently neglected fungi, protozoa, viruses, and archaeobacteria).

Non-bacterial organisms

While bacteria are the best-studied population within the urinary tract, we are beginning to see early explorations of other organism classes there, such as fungi and viruses.

Fungi—Viable fungi in urine were identified as early as the 1850s, with alterations in fungal composition noted in diabetes and renal disease [29]. Yet 150 years later, there has been little improvement in our understanding of urinary fungi. Several reports examining urinary microbiota using expanded culture conditions identified viable *Candida* species [30,

31•, 32], reiterating the viability of fungi from urinary samples obtained by catheterization. Targeted analysis of fungi using multi-locus PCR coupled with electrospray ionization/mass spectrometry revealed increased fungal DNA during symptomatic flares in patients with IC/BPS [33, 34•]. Fungal community profiling by NGS using the ITS1 region of fungal rRNA, however, revealed that the taxa detected in previous studies are only a small component of the complement of genera present in urinary specimens [35, 36].

Multiple issues are responsible for the lack of progress in fungal characterization, including inadequate fungal reference databases, challenges in the isolation and processing of these more robust organisms, and an erroneous belief that these organisms are not critical in human disease. An increasing number of diseases are being linked to fungal dysbiosis, implicating a profound impact on health and disease [37]. In addition, microbiota are a collective community; the importance of synergistic and antagonistic associations with other microbial components has likely been underestimated.

Viruses—Several studies have attempted to identify viral DNA from urine and link these to urinary symptomatology [38]. Viruses, however, lack conserved sequences to permit high-throughput amplification of conserved regions; it is necessary to perform either targeted detection of known viruses or mass DNA sequencing with subsequent viral identification after genomic reconstruction (metagenomic sequencing). Given the low urinary biomass and contaminating DNA, viral DNA may be a needle in the host DNA haystack. One study examining human papilloma viruses could not identify any associations with LUT symptomatology [39]. Another examined the correlation of JC polyoma viruses (JCPyV) with glomerulosclerosis, suggesting a protective effect for JCPyV [40]. Several recent studies were able to distinguish viral sequences from JCPyV and BK and Torque teno virus from urine after whole genome sequencing [41, 42]. As these reports examine urine, not tissue, such approaches may miss important viral reservoirs. Viral peptide mapping using mass spectroscopy-mediated proteomics avoids the pitfalls of genomic sequencing and has identified multiple novel viral proteins in urine, which occur at different frequencies in healthy subjects and patients with several renal diseases [43].

Bacteriophages—In the urine, genetic sequences of numerous bacteriophages, viruses that kill bacteria, were found within the genetic sequences of urinary bacteria, suggesting their presence within the urinary microbiome. Bacteriophages play a fundamental role in modulating bacterial communities [44]. A few recent studies have examined this population more comprehensively; analysis of genomic sequences obtained from prior studies revealed a diverse abundance of phages, many of which had little homology to previously described phages [45, 46•]. In addition, abundance of bacteriophage gene sequences differed between asymptomatic subjects and individuals with urinary symptoms, implicating an impact of phages on bladder health [46]. This influence on bacterial microbiota suggests obvious therapeutic potential; bacteriophages have already been proposed as a treatment for complicated urinary tract infection (UTI) [47] as well as biofilm encrustation of indwelling urinary devices [48].

The Urinary Microbiome in Disease

The preponderance of evidence implicates urinary microbes as at least a bystander in or a modifier or promoter of LUT disease. As with all studies of non-malignant LUT conditions, a strict definition of the patient population under study with rigorous inclusion and exclusion criteria is essential for success. A substantial proportion of women will objectively have urinary symptoms, but not complain of these when asked [49, 50]. Given the high prevalence of LUT symptoms, contamination of control groups with symptomatic patients may result in inconclusive or false negative results. For urologic research in general, better and more careful specification of study populations and careful screening of asymptomatic patients using multiple modalities will improve future research.

Urinary Incontinence—Most studies have focused on urgency urinary incontinence (UUI). Only one has primarily addressed stress urinary incontinence (SUI) and did not find any associations of microbiota with SUI symptoms, but did not compare these women to an age-matched control group [51].

Microbiota of UUI are by far the best studied, with multiple studies observing associations of the urinary microbes with symptoms [19, 20, 24, 26, 30, 52, 53]. The specific differences, however, are not consistent between studies, with little overlap or conflicting results between different research groups. One interesting study examined baseline differences in urinary microbiota prior to treatment with solifenacin, an anticholinergic given for UUI, linking increased *Actinomyces*, *Corynebacterium*, and *Streptococcus* abundances with improved responses to medication [20]. These data provide an intriguing potential prognostic factor for individualized UUI treatment decisions and suggest medications, such as beta3-agonists, may be able to modify the urinary microbiome.

Studies from multiple groups implicate variations in *Lactobacillus* species identity and abundance in UUI. *Lactobacillus* predominance appears to associate with healthy controls, while Lactobacilli within a more diverse population are associated with disease, despite no significant differences in lactobacillus abundance across populations [26]. *Lactobacillus* species also segregate with UUI, particularly *Lactobacillus gasseri* with UUI and *Lactobacillus crispatus* with healthy controls [30]. Control and UUI populations differed significantly in age, exogenous sex hormone usage, and body mass index, however, which likely impact these associations. While further larger-scale studies will be necessary to clarify UUI-associated microbial changes, a role for lactobacilli in health and disease appears likely.

Genitourinary Pain (IC/BPS and CP/CPPS)—For genitourinary pain syndromes, a single pathogen or microbial pattern is unlikely to cause all types of genitourinary pain. In a study by the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network, bacterial composition of voided urine from men with CPPS differed significantly from healthy controls, with *Burkholderia cenocepacia* overrepresented in affected subjects [54]. A second study of voided samples reiterated differences between CPPS and controls, with overrepresentation of *Clostridia* and *Bacteroides* and underrepresentation of *Bacilli* in affected patients [21].

In women, a single, small study of catheterized urine samples revealed decreased bacterial diversity, with reduced *Lactobacillus* levels and increased proinflammatory cytokines in IC/BPS compared with controls [22•]. Three studies examining voided urine samples in women with IC/BPS were unable to identify differences in individual taxa between control subjects and IC/BPS participants [55-57], but did observe trends towards differential abundances of several species, such as increased *L. gasseri* and lower *Corynebacterium* prevalence in IC/BPS patients. Earlier studies using both voided and catheterized specimens are similar, visualizing overall changes in diversity without unique disease-associated species. In all these studies, quantity and species variations in the individual *Lactobacillus* spp. were common although typically not significant and frequently contradictory between studies. In studies of the vaginal microbiota, *Lactobacillus* species and strain variations can highly influence disease [58, 59], which may explain this ambiguity and confusion. Collectively, these studies implicate a critical role for *Lactobacilli* in IC/BPS, but the nature of this role remains undefined.

An additional MAPP study of women with IC/BPS revealed increased levels of detectable fungi, particularly *Candida* spp., without changes in bacterial community patterns [34]. A follow-up study examining fungal taxa in detail revealed greater fungal diversity and increased fungal burden in IC/BPS subjects with increased urinary symptom severity [33]. Unfortunately, neither study compared IC/BPS with controls. Altered levels of *Lactobacilli* may implicate a possible connection; selective *Lactobacillus* species will inhibit *Candida* growth and hyphae formation [60, 61]. Another potential confounder is that IC/BPS is often treated with antibiotics empirically, especially during painful flares; antibiotics can result in fungal overrepresentation within microbial communities.

These contradictory and inconclusive studies of genitourinary pain only promote confusion regarding any role for or correlation with urinary microbial communities. Direct comparisons are challenging due to a lack of consistency in study structure and subject differentiation, making strict, homogeneous definitions of study populations necessary to differentiate pathologic correlates. We cannot expect conclusive findings from microbiome or any field of study until we meet this standard.

Urinary Tract Infection (UTI)—Our established diagnostic and management paradigm for UTI has come under fire with the revelation of a complex, symbiotic microbiome within the healthy genitourinary tract [62]. No consensus exists for a strict definition of UTI [63]; significant debate still surrounds the bacterial colony-forming unit-based thresholds that define infection by standard clinical urine culture. This uncertainty is compounded by the discovery that urinary bacteria can be detected in the urine of nearly all subjects, including those without urinary symptoms [64]. Thus, according to the strict definition, all individuals have “bacteriuria.”

Asymptomatic bacteriuria has been implicated as protective against recurrent UTI [65]; better understanding of the urinary microbiome suggests a mechanism for this clinical observation. Multiple asymptomatic bacteriuria strains exhibit reduced virulence and effective inhibition of subsequent colonization with uropathogenic *Escherichia coli* strains [66, 67]. Interspecies bacterial antagonism is an emerging theme in UTI prevention,

particularly with growing antibiotic resistance. Certain *Enterobacteriaceae*, including some asymptomatic bacteriuria *E. coli* strains, secrete a siderophore, escherichelin, that inhibits *Pseudomonas aeruginosa* from causing symptomatic infection [68]. In a comparative genomic study of *E. coli* isolates from women with recurrent UTI, the virulence potential of diverse bacterial strains significantly impacted UTI risk and outcome, stressing the importance of strain-level differences in bacterial uropathogenicity [69••]. Differences in virulence potential of *E. coli* strains similarly influence infection outcomes in prostatitis. Certain strains are associated with acute infection with subsequent clearance while others lead to persistence and pain [70]. Similar studies have noted significant strain effects for other species, which must reframe our concept of uropathogens and bacteriuria.

Novel diagnostic methods have capitalized on culture-independent DNA amplification–based molecular techniques for the improved detection of bacterial pathogens in urine from symptomatic patients. Such methods have the potential to rapidly identify causative organisms. While there is evidence that these methods may be able to recognize antibiotic susceptibility [71], avoiding inappropriate or delayed treatment, it is unclear how more sensitive detection methods will impact the accuracy of UTI diagnosis. Current understanding stresses that urinary bacteria are present in the healthy state, and that certain bacteria, even some historically considered uropathogens, may be beneficial to bladder health. Thus, more sensitive bacterial detection in the absence of clinical context may be associated with diagnostic confusion and unnecessary overtreatment. As urinary frequency and urgency are associated with multiple urologic conditions, dysuria remains a more accurate diagnostic marker than any bacterial, threshold-based measure [72]. Context and judgement are important, especially in light of evidence refuting the concept that any strict detection threshold or particular species is pathognomonic for UTI.

Early data also suggest a role for the vaginal microbiota in recurrent UTI [73]. In an animal model of recurrent UTI in which animals are chronically colonized with uropathogenic *E. coli*, urethral inoculation with *Gardnerella* will prompt healthy mice to redevelop an *E. coli* UTI [74•]. These data support the concept that endogenous microbes affecting the local, visceral environment modulate disease independent of frank infection.

Effects of Antibiotics on the Urinary Microbiome—No studies have directly examined the longitudinal effects of antibiotics on the healthy microbiome. While most studies of the urinary microbiome attempt to control for antibiotic effects by excluding patients with recent use, it is unclear what period free from treatment is needed to prevent confounding. The stable gut microbiome can be permanently perturbed by just two courses of ciprofloxacin, resulting in a stable alternative composition [75]. While causality is unclear, repeated antibiotic use has been linked to a variety of localized and systemic conditions such as depression, schizophrenia, and allergy/atopy [76-78].

With regard to the urinary microbiome, a few studies have implicated systemic antibiotic effects in this biological niche. In a small study of 27 subjects, prior antibiotic use was associated with decreased *Lactobacillus* and *Finegoldia* and increased *E. coli* and *Parabacteroides* [79•]. In women given oral metronidazole for bacterial vaginosis, the relative abundances of BV-associated pathogens such as *Gardnerella vaginalis*, *Atopobium*

vaginae, and *Sneathia amnii* decreased, but did not disappear, and remained at levels not significantly different from those seen in asymptomatic controls [80]. After metronidazole treatment, increases in *Lactobacillus iners* were seen in vaginal and urinary specimens, and *Lactobacillus crispatus*, which commonly predominates in healthy, pre-menopausal women, became undetectable in urinary specimens after treatment despite persistence in vaginal samples.

In renal transplant recipients, urine samples taken 1 month after surgery demonstrate increased bacterial diversity as well as increased relative abundances of *Enterococcus*, *Escherichia coli*, *Gardnerella*, and *Prevotella* [18, 81]. As antibiotic suppression is standard for patients post-transplant, these changes were suspected to be due to daily antibiotic usage, but one cannot rule out effects of the metabolic and inflammatory dysregulation of chronic renal failure, transplantation surgery stress, and immunosuppression.

While it is unclear if such genitourinary dysbiosis is the result of antimicrobial drug use or a risk factor for urinary tract infections, data suggest that antimicrobials modify the urinary microbiome, possibly selecting for more pathogenic bacteria with increased antibiotic resistance. The long-term consequences of these shifts are unclear but urge caution when considering therapeutic antimicrobial interventions. Furthermore, antibiotics for non-urologic indications may have unintended alterations to urinary microbiota.

Genitourinary Malignancies—Intravesical instillation of *Bacille Calmette-Guerin* (BCG), a live mycobacterium strain, has long been used for therapeutic manipulation of urinary microbiota as treatment of non-muscle invasive bladder urothelial carcinoma, demonstrating the potential effect of bacteria on cancer progression. Several studies identified pre-treatment differences in urinary communities between patients with bladder cancer and healthy controls [82, 83]. Increased levels of *Fusobacterium*, which is pro-tumorigenic in colonic malignancies [84, 85], were identified in patients with bladder cancer in comparison with controls [82]. While correlative at this point, the tumor promotional potential of the urinary microbiome promotes an interesting hypothesis for the gender differences observed in bladder cancer incidence [86]. Healthy women at baseline have a higher abundance of *Mycobacteria* and other *Actinomycetes* [87], which have been hypothesized to have an inhibitory effect on cancer promotion or progression. While immature, hints of evidence suggest certain urinary microbial profiles are associated with risk of cancer recurrence, progression, and treatment responses [83].

Urolithiasis—Urinary stone disease is highly prevalent, affecting almost 10% of the US population, and linked to metabolic disorders, such as atherosclerosis, obesity, and diabetes mellitus [88]. The relationship between the gut microbiota, oxalate metabolism, and stone formation has been well described in animal models and human populations [89-92]. The role of urease-producing bacteria in the generation and promotion of struvite stones has long been accepted, but only in the past few years, however, have culture-independent techniques been applied to further our understanding of the role of urinary bacteria in urolithiasis.

Several studies have identified an enriched, altered group of bacteria in association with urinary stones, suggesting specific genera contribute to the urolithiasis pathophysiology

[93]. Stone cultures yielded bacterial and even fungal growth, even after surgical removal and perioperative antibiotics, indicating that microbes are viable within the stone fragments. While these bacteria are not urease-producing, many of the isolated genera promote crystal aggregation in vitro [94-96] which promotes stone formation [97]. Bacteria may also decrease citrate levels in urine via bacterial production of citrate lyase, which also promotes stone formation [98]. While urinary microbiota likely function in the promotion of urolithiasis, additional research is needed to understand its role in nidus formation and stone promotion as well as any possible protective role for alternative genera in the larger urinary milieu.

Conclusions and Future Directions

Advances in microbiome science promote a vision of the future in which tailored adjustments in an individual's resident communities can be exploited to improve health and combat disease. The substantial knowledge gap between this potential future and our present, however, requires a deeper dive into the basic host-microbe and microbe-microbe interactions within the LUT, including a characterization of microbial variability over time; the impact of environmental stressors, dietary intake, and medications on urinary microbial composition; and the consequences of microbial shifts on LUT function, all of which are unstudied. Also, increased granular understanding of host response mechanisms to the urinary microbiome, both in healthy and disease states, is lagging behind the burgeoning numbers of descriptive urinary microbiome studies. While cataloguing studies describe the constituents, from bacteria to bacteriophages, of the urinary microbiome in healthy and diseased hosts, it is "mission critical" to frame these taxonomical studies as to why and how the host responds (or does not respond) to these microbial communities.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
 - Of major importance
1. Whiteside SA, Razvi H, Dave S, Reid G, Burton JP. The microbiome of the urinary tract—a role beyond infection. *Nat Rev Urol*. 2015;12(2):81–90. 10.1038/nrurol.2014.361. [PubMed: 25600098]
 2. Thomas-White K, Brady M, Wolfe AJ, Mueller ER. The bladder is not sterile: history and current discoveries on the urinary microbiome. *Curr Bladder Dysfunct Rep*. 2016;11(1):18–24. 10.1007/s11884-016-0345-8. [PubMed: 27182288]
 - 3••. Karstens L, Asquith M, Caruso V, Rosenbaum JT, Fair DA, Braun J, et al. Community profiling of the urinary microbiota: considerations for low-biomass samples. *Nat Rev Urol*. 2018;15(12):735–49. 10.1038/s41585-018-0104-z [PubMed: 30315209] This is an in-depth exploration of the detailed decisions in the analysis of microbial sequence data that can influence the results and findings of microbiome studies of the urinary tract.
 - 4•. Wolfe AJ, Toh E, Shibata N, Rong R, Kenton K, Fitzgerald M, et al. Evidence of uncultivated bacteria in the adult female bladder. *J Clin Microbiol*. 2012;50(4):1376–83. 10.1128/JCM.05852 [PubMed: 22278835] One of the first descriptions of the presence of bacteria within the urinary tract; it is also the only study to detail the profound differences in microbial communities detected with different methods of sampling the urinary tract.

5. Ackerman AL, Khalique MU, Ackerman JE, Tang J, Kim J, Underhill DM et al. Optimization of DNA extraction from human urinary samples for mycobiome community profiling. *PLoS One*. 2019;14(4).
6. Caruso V, Song X, Asquith M, Karstens L. Performance of microbiome sequence inference methods in environments with varying biomass. *mSystems*. 2019;4(1). doi:10.1128/mSystems.00163-18.
7. Ghannoum MA, Jurevic RJ, Mukherjee PK, Cui F, Sikaroodi M, Naqvi A, et al. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. *PLoS Pathog*. 2010;6(1):e1000713 10.1371/journal.ppat.1000713. [PubMed: 20072605]
8. Dollive S, Peterfreund GL, Sherrill-Mix S, Bittinger K, Sinha R, Hoffmann C, et al. A tool kit for quantifying eukaryotic rRNA gene sequences from human microbiome samples. *Genome Biol*. 2012;13(7):R60 10.1186/gb-2012-13-7-r60. [PubMed: 22759449]
9. Wu GD, Lewis JD, Hoffmann C, Chen YY, Knight R, Bittinger K, et al. Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. *BMC Microbiol*. 2010;10:206 10.1186/1471-2180-10-206. [PubMed: 20673359]
10. Yuan S, Cohen DB, Ravel J, Abdo Z, Forney LJ. Evaluation of methods for the extraction and purification of DNA from the human microbiome. *PLoS One*. 2012;7(3):e33865 10.1371/journal.pone.0033865. [PubMed: 22457796]
11. Bao Y, Al KF, Chanyi RM, Whiteside S, Dewar M, Razvi H, et al. Questions and challenges associated with studying the microbiome of the urinary tract. *Ann Transl Med*. 2017;5(2):33 10.21037/atm.2016.12.14. [PubMed: 28217698]
12. Earl JP, Adappa ND, Krol J, Bhat AS, Balashov S, Ehrlich RL, et al. Species-level bacterial community profiling of the healthy sinonasal microbiome using Pacific Biosciences sequencing of full-length 16S rRNA genes. *Microbiome*. 2018;6(1):190 10.1186/s40168-018-0569-2. [PubMed: 30352611]
13. Sianou A, Galyfos G, Kaparos G. Re: Alan J. Wolfe, Linda Brubaker. "Sterile urine" and the presence of bacteria. *Eur Urol* 2015;68:173-4. *Eur Urol*. 2016;69(1):e7. doi:10.1016/j.eururo.2015.06.052. [PubMed: 26168696]
14. Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans AD, de Vos WM. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. *Appl Environ Microbiol*. 2002;68(7):3401-7. 10.1128/aem.68.7.3401-3407.2002. [PubMed: 12089021]
15. Momozawa Y, Deffontaine V, Louis E, Medrano JF. Characterization of bacteria in biopsies of colon and stools by high throughput sequencing of the V2 region of bacterial 16S rRNA gene in human. *PLoS One*. 2011;6(2):e16952 10.1371/journal.pone.0016952. [PubMed: 21347324]
- 16•. Thomas-White K, Forster SC, Kumar N, Van Kuiken M, Putonti C, Stares MD, et al. Culturing of female bladder bacteria reveals an interconnected urogenital microbiota. *Nat Commun*. 2018;9(1):1557 10.1038/s41467-018-03968-5 [PubMed: 29674608] Cross-sectional sampling of the urogenital tract in a cohort of female patients reveals strong interrelationship between the vaginal and urinary microbiome that may suggest an interconnected urogenital microbiome, at least in women.
17. Liu F, Ling Z, Xiao Y, Lv L, Yang Q, Wang B, et al. Dysbiosis of urinary microbiota is positively correlated with type 2 diabetes mellitus. *Oncotarget*. 2017;8(3):3798-810. 10.18632/oncotarget.14028. [PubMed: 28008148]
18. Rani A, Ranjan R, McGee HS, Andropolis KE, Panchal DV, Hajjiri Z, et al. Urinary microbiome of kidney transplant patients reveals dysbiosis with potential for antibiotic resistance. *Transl Res*. 2017;181:59-70. 10.1016/j.trsl.2016.08.008. [PubMed: 27669488]
19. Karstens L, Asquith M, Davin S, Stauffer P, Fair D, Gregory WT, et al. Does the urinary microbiome play a role in urgency urinary incontinence and its severity? *Front Cell Infect Microbiol*. 2016;6:78 10.3389/fcimb.2016.00078. [PubMed: 27512653]
- 20•. Thomas-White KJ, Hilt EE, Fok C, Pearce MM, Mueller ER, Kliethermes S, et al. Incontinence medication response relates to the female urinary microbiota. *Int Urogynecol J*. 2016;27(5):723-33. 10.1007/s00192-015-2847-x [PubMed: 26423260] The baseline urinary microbiome prior to treatment in a population of women with UUI was related to medication responses, providing the first evidence that the urinary microbiome may be a useful prognostic biomarker in the classification of patients with benign urologic conditions.

21. Shoskes DA, Altemus J, Polackwich AS, Tucky B, Wang H, Eng C. The urinary microbiome differs significantly between patients with chronic prostatitis/chronic pelvic pain syndrome and controls as well as between patients with different clinical phenotypes. *Urology*. 2016;92:26–32. 10.1016/j.urology.2016.02.043. [PubMed: 26970449]
22. Abernethy MG, Rosenfeld A, White JR, Mueller MG, Lewicky-Gaupp C, Kenton K. Urinary microbiome and cytokine levels in women with interstitial cystitis. *Obstet Gynecol*. 2017;129(3):500–6. 10.1097/AOG.0000000000001892 [PubMed: 28178051] This small study of a cohort of women with interstitial cystitis and age-matched controls identified alterations in the microbiome that also correlated with both increased inflammatory cytokine levels and worsening symptom scores, suggesting a functional consequence associated with shifts in urogenital microbial communities.
23. Kramer H, Kuffel G, Thomas-White K, Wolfe AJ, Vellanki K, Leehey DJ, et al. Diversity of the midstream urine microbiome in adults with chronic kidney disease. *Int Urol Nephrol*. 2018;50(6):1123–30. 10.1007/s11255-018-1860-7. [PubMed: 29651696]
24. Wu P, Chen Y, Zhao J, Zhang G, Chen J, Wang J, et al. Urinary microbiome and psychological factors in women with overactive bladder. *Front Cell Infect Microbiol*. 2017;7:488 10.3389/fcimb.2017.00488. [PubMed: 29230385]
25. Curtiss N, Balachandran A, Krska L, Peppiatt-Wildman C, Wildman S, Duckett J. Age, menopausal status and the bladder microbiome. *Eur J Obstet Gynecol Reprod Biol*. 2018;228:126–9. 10.1016/j.ejogrb.2018.06.011. [PubMed: 29936400]
26. Komesu YM, Richter HE, Carper B, Dinwiddie DL, Lukacz ES, Siddiqui NY, et al. The urinary microbiome in women with mixed urinary incontinence compared to similarly aged controls. *Int Urogynecol J*. 2018;29(12):1785–95. 10.1007/s00192-018-3683-6. [PubMed: 29909556]
27. Komesu YM, Richter HE, Dinwiddie DL, Siddiqui NY, Sung VW, Lukacz ES, et al. Methodology for a vaginal and urinary microbiome study in women with mixed urinary incontinence. *Int Urogynecol J*. 2017;28(5):711–20. 10.1007/s00192-016-3165-7. [PubMed: 27738739]
28. Liu F, Ling Z, Xiao Y, Yang Q, Zheng L, Jiang P, et al. Characterization of the urinary microbiota of elderly women and the effects of type 2 diabetes and urinary tract infections on the microbiota. *Oncotarget*. 2017;8(59):100678–90. 10.18632/oncotarget.21126. [PubMed: 29246012]
29. Hassall A On the development of torulae in the urine, and on the relation of these fungi to albuminous and saccharine urine. *Med Chir Trans*. 1853;36:23–789. 10.1177/095952875303600103.
30. Pearce MM, Hilt EE, Rosenfeld AB, Zilliox MJ, Thomas-White K, Fok C, et al. The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. *mBio*. 2014;5(4):e01283–14. 10.1128/mBio.01283-14. [PubMed: 25006228]
31. Hilt EE, McKinley K, Pearce MM, Rosenfeld AB, Zilliox MJ, Mueller ER, et al. Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder. *J Clin Microbiol*. 2014;52(3):871–6. 10.1128/JCM.02876-13 [PubMed: 24371246] This paper describes the use of an enhanced culture technique to show that multiple genera of bacteria are culturable from urine obtained by catheterization from asymptomatic women.
32. Price TK, Dune T, Hilt EE, Thomas-White KJ, Kliethermes S, Brincat C, et al. The clinical urine culture: enhanced techniques improve detection of clinically relevant microorganisms. *J Clin Microbiol*. 2016;54(5):1216–22. 10.1128/JCM.00044-16. [PubMed: 26962083]
33. Nickel JC, Stephens A, Landis JR, Mullins C, van Bokhoven A, Anger JT, et al. Urinary fungi associated with urinary symptom severity among women with interstitial cystitis/bladder pain syndrome (IC/BPS). *World J Urol*. 2019 10.1007/s00345-019-02764-0.
34. Nickel JC, Stephens A, Landis JR, Mullins C, van Bokhoven A, Lucia MS, et al. Assessment of the lower urinary tract microbiota during symptom flare in women with urologic chronic pelvic pain syndrome: a MAPP network study. *J Urol*. 2016;195(2):356–62. 10.1016/j.juro.2015.09.075 [PubMed: 26410734] In a large cohort of patients with urologic chronic pelvic pain syndrome, an association of worsening symptoms, dubbed symptomatic “flares”, was associated with increased detection of urinary fungi, revealing an importance for non-bacterial organisms in disease is being increasingly recognized for other organ systems.

35. Ackerman AL, Underhill DM. The mycobiome of the human urinary tract: potential roles for fungi in urology. *Ann Transl Med.* 2017;5(2):31 10.21037/atm.2016.12.69. [PubMed: 28217696]
36. Wheeler ML, Limon JJ, Bar AS, Leal CA, Gargus M, Tang J, et al. Immunological consequences of intestinal fungal dysbiosis. *Cell Host Microbe.* 2016;19(6):865–73. 10.1016/j.chom.2016.05.003. [PubMed: 27237365]
37. El-Jurdi N, Ghannoum MA. The mycobiome: impact on health and disease states. *Microbiol Spectr.* 2017;5(3). doi:10.1128/microbiolspec.FUNK-0045-2016.
38. Santiago-Rodriguez TM. Identification and quantification of DNA viral populations in human urine using next-generation sequencing approaches. *Methods Mol Biol.* 1838;2018:191–200. 10.1007/978-1-4939-8682-8_14.
39. Santiago-Rodriguez TM, Ly M, Bonilla N, Pride DT. The human urine virome in association with urinary tract infections. *Front Microbiol.* 2015;6:14 10.3389/fmicb.2015.00014. [PubMed: 25667584]
40. Divers J, Langeveld CD, Lyles DS, Ma L, Freedman BI. Protective association between JC polyoma viruria and kidney disease. *Curr Opin Nephrol Hypertens.* 2019;28(1):65–9. 10.1097/MNH.0000000000000464. [PubMed: 30320619]
41. Rani A, Ranjan R, McGee HS, Metwally A, Hajjiri Z, Brennan DC, et al. A diverse virome in kidney transplant patients contains multiple viral subtypes with distinct polymorphisms. *Sci Rep.* 2016;6:33327 10.1038/srep33327. [PubMed: 27633952]
42. Garretto A, Thomas-White K, Wolfe AJ, Putonti C. Detecting viral genomes in the female urinary microbiome. *J Gen Virol.* 2018;99(8):1141–6. 10.1099/jgv.0.001097. [PubMed: 29889019]
43. Sigdel TK, Mercer N, Nandoe S, Nicora CD, Burnum-Johnson K, Qian WJ, et al. Urinary virome perturbations in kidney transplantation. *Front Med (Lausanne).* 2018;5:72 10.3389/fmed.2018.00072. [PubMed: 29725592]
44. Garretto A, Miller-Ensminger T, Wolfe AJ, Putonti C. Bacteriophages of the lower urinary tract. *Nat Rev Urol.* 2019;16(7):422–32. 10.1038/s41585-019-0192-4. [PubMed: 31073244]
45. Malki K, Shapiro JW, Price TK, Hilt EE, Thomas-White K, Sircar T, et al. Genomes of Gardnerella strains reveal an abundance of prophages within the bladder microbiome. *PLoS One.* 2016;11(11):e0166757 10.1371/journal.pone.0166757. [PubMed: 27861551]
46. Miller-Ensminger T, Garretto A, Brenner J, Thomas-White K, Zambom A, Wolfe AJ et al. Bacteriophages of the urinary microbiome. *J Bacteriol.* 2018;200(7). doi:10.1128/JB.00738-17This study provides early evidence of the existence of abundant and novel bacteriophages within the urinary tract that likely influence both the composition of the urinary microbiome as well as urologic disease.
47. Ujmajuridze A, Chanishvili N, Goderdzishvili M, Leitner L, Mehnert U, Chkhotua A, et al. Adapted bacteriophages for treating urinary tract infections. *Front Microbiol.* 2018;9:1832 10.3389/fmicb.2018.01832. [PubMed: 30131795]
48. Nzakizwanayo J, Hanin A, Alves DR, McCutcheon B, Dedi C, Salvage J, et al. Bacteriophage can prevent encrustation and blockage of urinary catheters by *Proteus mirabilis*. *Antimicrob Agents Chemother.* 2015;60(3):1530–6. 10.1128/AAC.02685-15. [PubMed: 26711744]
49. Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. *BJU Int.* 2009;104(3):352–60. 10.1111/j.1464-410X.2009.08427.x. [PubMed: 19281467]
50. Ackerman AL, Lai HH, Parameshwar PS, Eilber KS, Anger JT. Symptomatic overlap in overactive bladder and interstitial cystitis/painful bladder syndrome - development of a new algorithm. *BJU Int.* 2018 10.1111/bju.14568.
51. Thomas-White KJ, Kliethermes S, Rickey L, Lukacz ES, Richter HE, Moalli P, et al. Evaluation of the urinary microbiota of women with uncomplicated stress urinary incontinence. *Am J Obstet Gynecol.* 2017;216(1):55e1–e16. 10.1016/j.ajog.2016.07.049. [PubMed: 27498309]
52. Fok CS, Gao X, Lin H, Thomas-White KJ, Mueller ER, Wolfe AJ, et al. Urinary symptoms are associated with certain urinary microbes in urogynecologic surgical patients. *Int Urogynecol J.* 2018;29(12):1765–71. 10.1007/s00192-018-3732-1. [PubMed: 30116843]

53. Pearce MM, Zilliox MJ, Rosenfeld AB, Thomas-White KJ, Richter HE, Nager CW, et al. The female urinary microbiome in urgency urinary incontinence. *Am J Obstet Gynecol*. 2015;213(3):347 e1–11. 10.1016/j.ajog.2015.07.009. [PubMed: 26210757]
54. Nickel JC, Stephens A, Landis JR, Chen J, Mullins C, van Bokhoven A, et al. Search for microorganisms in men with urologic chronic pelvic pain syndrome: a culture-independent analysis in the MAPP Research Network. *J Urol*. 2015;194(1):127–35. 10.1016/j.juro.2015.01.037. [PubMed: 25596358]
55. Bresler L, Price TK, Hilt EE, Joyce C, Fitzgerald CM, Wolfe AJ. Female lower urinary tract microbiota do not associate with IC/PBS symptoms: a case-controlled study. *Int Urogynecol J*. 2019 10.1007/s00192-019-03942-9.
56. Nickel JC, Stephens-Shields AJ, Landis JR, Mullins C, van Bokhoven A, Lucia MS et al. A culture-independent analysis of the microbiota of female interstitial cystitis/bladder pain syndrome participants in the MAPP Research Network. *J Clin Med*. 2019;8(3). doi:10.3390/jcm8030415.
57. Meriwether KV, Lei Z, Singh R, Gaskins J, DTG H, Jala V. The vaginal and urinary microbiomes in premenopausal women with interstitial cystitis/bladder pain syndrome as compared to unaffected controls: a pilot cross-sectional study. *Front Cell Infect Microbiol*. 2019;9:92 10.3389/fcimb.2019.00092. [PubMed: 31024861]
58. Greenbaum S, Greenbaum G, Moran-Gilad J, Weintraub AY. Ecological dynamics of the vaginal microbiome in relation to health and disease. *Am J Obstet Gynecol*. 2019;220(4):324–35. 10.1016/j.ajog.2018.11.1089. [PubMed: 30447213]
59. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, et al. Vaginal microbiome of reproductive-age women. *Proc Natl Acad Sci U S A*. 2011;108(Suppl 1):4680–7. 10.1073/pnas.1002611107. [PubMed: 20534435]
60. De Gregorio PR, Silva JA, Marchesi A, Nader-Macias MEF. Anti-Candida activity of beneficial vaginal lactobacilli in in vitro assays and in a murine experimental model. *FEMS Yeast Res*. 2019;19(2). doi:10.1093/femsyr/foz008.
61. Jang SJ, Lee K, Kwon B, You HJ, Ko G. Vaginal lactobacilli inhibit growth and hyphae formation of *Candida albicans*. *Sci Rep*. 2019;9(1):8121 10.1038/s41598-019-44579-4. [PubMed: 31148560]
62. Finucane TE. 'Urinary tract infection' and the microbiome. *Am J Med*. 2017;130(3):e97–e8. 10.1016/j.amjmed.2016.08.018. [PubMed: 27593612]
63. Anger J, Lee U, Ackerman AL, Chou R, Chughtai B, Clemens JQ et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU Guideline. *J Urol*. 2019;101097JU0000000000000296. doi:10.1097/JU.0000000000000296.
64. Price TK, Hilt EE, Dune TJ, Mueller ER, Wolfe AJ, Brubaker L. Urine trouble: should we think differently about UTI? *Int Urogynecol J*. 2018;29(2):205–10. 10.1007/s00192-017-3528-8. [PubMed: 29279968]
65. Cai T, Mazzoli S, Mondaini N, Meacci F, Nesi G, D'Elia C, et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? *Clin Infect Dis*. 2012;55(6):771–7. 10.1093/cid/cis534. [PubMed: 22677710]
66. Roos V, Ulett GC, Schembri MA, Klemm P. The asymptomatic bacteriuria *Escherichia coli* strain 83972 outcompetes uropathogenic *E. coli* strains in human urine. *Infect Immun*. 2006;74(1):615–24. 10.1128/IAI.74.U615-624.2006. [PubMed: 16369018]
67. Stork C, Kovacs B, Rozsai B, Putze J, Kiel M, Dorn A, et al. Characterization of asymptomatic bacteriuria *Escherichia coli* isolates in search of alternative strains for efficient bacterial interference against uropathogens. *Front Microbiol*. 2018;9:214 10.3389/fmicb.2018.00214. [PubMed: 29491858]
68. Ohlemacher SI, Giblin DE, d'Avignon DA, Stapleton AE, Trautner BW, Henderson JP. Enterobacteria secrete an inhibitor of *Pseudomonas* virulence during clinical bacteriuria. *J Clin Invest*. 2017;127(11):4018–30. 10.1172/JCI92464. [PubMed: 28945201]
69. Schreiber HL, Conover MS, Chou WC, Hibbing ME, Manson AL, Dodson KW et al. Bacterial virulence phenotypes of *Escherichia coli* and host susceptibility determine risk for urinary tract infections. *Sci Transl Med*. 2017;9(382). doi:10.1126/scitranslmed.aaf1283. This comparative genomic study examining a panel of *E. coli* isolates from women with urinary tract infections

revealed conserved functional, but not genomic, virulence patterns at the bacterial strain level, suggesting important host-pathogen interactions at the root of infection susceptibility.

70. Krieger JN, Thumbikat P. Bacterial Prostatitis: Bacterial Virulence, Clinical outcomes, and new directions. *Microbiol Spectr*. 2016;4(1). doi:10.1128/microbiolspec.UTI-0004-2012.
71. Tchesnokova V, Avagyan H, Rechkina E, Chan D, Muradova M, Haile HG, et al. Bacterial clonal diagnostics as a tool for evidence-based empiric antibiotic selection. *PLoS One*. 2017;12(3):e0174132 10.1371/journal.pone.0174132. [PubMed: 28350870]
72. Dune TJ, Price TK, Hilt EE, Thomas-White KJ, Kliethermes S, Brincat C, et al. Urinary symptoms and their associations with urinary tract infections in urogynecologic patients. *Obstet Gynecol*. 2017;130(4):718–25. 10.1097/AOG.0000000000002239. [PubMed: 28885414]
73. Stapleton AE. The vaginal microbiota and urinary tract infection. *Microbiol Spectr*. 2016;4(6). doi:10.1128/microbiolspec.UTI-0025-2016.
74. Gilbert NM, O'Brien VP, Lewis AL. Transient microbiota exposures activate dormant *Escherichia coli* infection in the bladder and drive severe outcomes of recurrent disease. *PLoS Pathog*. 2017;13(3):e1006238 10.1371/journal.ppat.1006238 [PubMed: 28358889] In mice primed for recurrent urinary tract infections, intraurethral inoculation of *Gardnerella*, a bacterium associated in humans with bacterial vaginosis, can promote the development of *E. coli* urinary tract infection, suggesting that infection risk is a complex interplay not only between host and pathogen but that the microbial environment can also promote infection.
75. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. *Proc Natl Acad Sci U S A*. 2011;108(Suppl 1):4554–61. 10.1073/pnas.1000087107. [PubMed: 20847294]
76. Kohler O, Petersen L, Mors O, Mortensen PB, Yolken RH, Gasse C, et al. Infections and exposure to anti-infective agents and the risk of severe mental disorders: a nationwide study. *Acta Psychiatr Scand*. 2017;135(2):97–105. 10.1111/acps.12671. [PubMed: 27870529]
77. Kohler-Forsberg O, Petersen L, Gasse C, Mortensen PB, Dalsgaard S, Yolken RH, et al. A nationwide study in denmark of the association between treated infections and the subsequent risk of treated mental disorders in children and adolescents. *JAMA Psychiatry*. 2018 10.1001/jamapsychiatry.2018.3428.
78. Noverr MC, Falkowski NR, McDonald RA, McKenzie AN, Huffnagle GB. Development of allergic airway disease in mice following antibiotic therapy and fungal microbiota increase: role of host genetics, antigen, and interleukin-13. *Infect Immun*. 2005;73(1):30–8. 10.1128/IAI.73.130-38.2005. [PubMed: 15618138]
79. Mulder M, Radjabzadeh D, Hassing RJ, Heeringa J, Uitterlinden AG, Kraaij R, et al. The effect of antimicrobial drug use on the composition of the genitourinary microbiota in an elderly population. *BMC Microbiol*. 2019;19(1):9 10.1186/s12866-018-1379-1 [PubMed: 30626324] Despite widespread use of antibiotics to treat uropathogens such as *E. coli*, this examination of older adults after treatment with antibiotics revealed decreases in the classic anti-inflammatory commensals such as *Lactobacillus* and increases in *E. coli* after treatment, which should caution the use of antimicrobials for “Eradication” of uropathogens, particularly in asymptomatic patients.
80. Gottschick C, Deng ZL, Vital M, Masur C, Abels C, Pieper DH, et al. The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. *Microbiome*. 2017;5(1):99 10.1186/s40168-017-0305-3. [PubMed: 28807017]
81. Modena BD, Milam R, Harrison F, Cheeseman JA, Abecassis MM, Friedewald JJ, et al. Changes in urinary microbiome populations correlate in kidney transplants with interstitial fibrosis and tubular atrophy documented in early surveillance biopsies. *Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg*. 2017;17(3):712–23. 10.1111/ajt.14038.
82. Bucevic Popovic V, Situm M, Chow CT, Chan LS, Roje B, Terzic J. The urinary microbiome associated with bladder cancer. *Sci Rep*. 2018;8(1):12157 10.1038/s41598-018-29054-w. [PubMed: 30108246]
83. Wu P, Zhang G, Zhao J, Chen J, Chen Y, Huang W, et al. Profiling the urinary microbiota in male patients with bladder cancer in China. *Front Cell Infect Microbiol*. 2018;8:167 10.3389/fcimb.2018.00167. [PubMed: 29904624]

84. Viljoen KS, Dakshinamurthy A, Goldberg P, Blackburn JM. Quantitative profiling of colorectal cancer-associated bacteria reveals associations between fusobacterium spp., enterotoxigenic *Bacteroides fragilis* (ETBF) and clinicopathological features of colorectal cancer. *PLoS One*. 2015;10(3):e0119462 10.1371/journal.pone.0119462. [PubMed: 25751261]
85. Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, et al. Analysis of *Fusobacterium* persistence and antibiotic response in colorectal cancer. *Science*. 2017;358(6369):1443–8. 10.1126/science.aal5240. [PubMed: 29170280]
86. Raoult D Is there a link between urinary microbiota and bladder cancer? *Eur J Epidemiol*. 2017;32(3):255 10.1007/s10654-016-0213-z. [PubMed: 28013490]
87. Lewis DA, Brown R, Williams J, White P, Jacobson SK, Marchesi JR, et al. The human urinary microbiome; bacterial DNA in voided urine of asymptomatic adults. *Front Cell Infect Microbiol*. 2013;3:41 10.3389/fcimb.2013.00041. [PubMed: 23967406]
88. Lee JA, Stern JM. Understanding the link between gut microbiome and urinary stone disease. *Curr Urol Rep*. 2019;20(5):19 10.1007/s11934-019-0882-8. [PubMed: 30903295]
89. Tang R, Jiang Y, Tan A, Ye J, Xian X, Xie Y, et al. 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones. *Urolithiasis*. 2018;46(6):503–14. 10.1007/s00240-018-1037-y. [PubMed: 29353409]
90. Stern JM, Moazami S, Qiu Y, Kurland I, Chen Z, Agalliu I, et al. Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers. *Urolithiasis*. 2016;44(5):399–407. 10.1007/s00240-016-0882-9. [PubMed: 27115405]
91. Suryavanshi MV, Bhute SS, Jadhav SD, Bhatia MS, Gune RP, Shouche YS. Hyperoxaluria leads to dysbiosis and drives selective enrichment of oxalate metabolizing bacterial species in recurrent kidney stone endures. *Sci Rep*. 2016;6:34712 10.1038/srep34712. [PubMed: 27708409]
92. Ticinesi A, Milani C, Guerra A, Allegrì F, Lauretani F, Nouvenne A, et al. Understanding the gut-kidney axis in nephrolithiasis: an analysis of the gut microbiota composition and functionality of stone formers. *Gut*. 2018;67(12):2097–106. 10.1136/gutjnl-2017-315734. [PubMed: 29705728]
93. Dornbier RA, Bajic P, Van Kuiken M, Jardaneh A, Lin H, Gao X, et al. The microbiome of calcium-based urinary stones. *Urolithiasis*. 2019 10.1007/s00240-019-01146-w.
94. Amimanan P, Tavichakorntrakool R, Fong-Ngern K, Sribenjalux P, Lulitanond A, Prasongwatana V, et al. Elongation factor Tu on *Escherichia coli* isolated from urine of kidney stone patients promotes calcium oxalate crystal growth and aggregation. *Sci Rep*. 2017;7(1):2953 10.1038/s41598-017-03213-x. [PubMed: 28592876]
95. Barr-Beare E, Saxena V, Hilt EE, Thomas-White K, Schober M, Li A, et al. The interaction between Enterobacteriaceae and calcium oxalate deposits. *PLoS One*. 2015;10(10):e0139575 10.1371/journal.pone.0139575. [PubMed: 26448465]
96. Chutipongtanate S, Sutthimethakorn S, Chiangjong W, Thongboonkerd V. Bacteria can promote calcium oxalate crystal growth and aggregation. *J Biol Inorg Chem*. 2013;18(3):299–308. 10.1007/s00775-012-0974-0. [PubMed: 23334195]
97. Schwaderer AL, Wolfe AJ. The association between bacteria and urinary stones. *Annals of translational medicine*. 2017;5(2):32 10.21037/atm.2016.11.73. [PubMed: 28217697]
98. De Ferrari ME, Macaluso M, Brunati C, Pozzoli R, Colussi G. Hypocitraturia and *Ureaplasma urealyticum* urinary tract infection in patients with idiopathic calcium nephrolithiasis. *Nephrol Dial Transplant*. 1996;11(6):1185 10.1093/oxfordjournals.ndt.a027486. [PubMed: 8671996]

Fig. 1.

The proposed role of urinary dysbiosis in the development of urinary pathology. (A) In a healthy bladder, a symbiotic microbiota maintains the urothelial barrier, prevents pathologic infection, and preserves normal neurotransmission. (B) In patients with bladder dysfunction, a dysbiotic urinary microflora alters bladder function and results in pain. (1) Pathobiont microbes, enriched in urinary dysbiosis, interact with a susceptible host immune system to induce inflammation. (2) Infiltration of immune cells and inflammatory mediator production (cytokines and chemokines) in concert with loss of the pro-homeostatic, microbially associated factors leads to a breakdown of the urothelial barrier and increased tissue permeability. (3) Host inflammation leads to increased vascularity, tissue edema, and leukocyte recruitment. (4) These fundamental changes in the bladder microenvironment lead to changes in both sensory and motor neurotransmission, leading to sequelae such as altered pain thresholds or detrusor muscle overactivity